Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline and Astex reorganise collaborative arrangements

GlaxoSmithKline and Astex reorganise collaborative arrangements

17th January 2012

GlaxoSmithKline and Astex Pharmaceuticals have agreed to amend their collaborative partnership in the area of epigenetics.

Astex has decided to call an early end to the Climb epigenetic collaboration agreed between its predecessor SuperGen and GlaxoSmithKline in November 2009, following a review of Astex's pipeline.

Following this move, existing research work and assets relating to the project will be transferred to GlaxoSmithKline, with Astex receiving milestones and royalties under an asset transfer agreement.

This will not affect the separate multi-target drug discovery arrangement between GlaxoSmithKline and Astex Therapeutics, which involves the identification of molecules using the Pyramid fragment platform.

Dr Harren Jhoti, president of Astex Pharmaceuticals, said: "The decision to transfer the Climb epigenetic program to GlaxoSmithKline was based on our assessment of internal resources and discussions with GlaxoSmithKline."

Last month, GlaxoSmithKline allied with ProteoTech on a new project that will aim to create a new therapy option for Parkinson's disease.ADNFCR-8000103-ID-801266343-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.